Printer Friendly

HEALTH CARE FINANCE ADMINISTRATION RECOMMENDS REIMBURSEMENT OF DUAL-ENERGY X-RAY EXAMINATIONS FOR OSTEOPOROSIS TESTING

 WALTHAM, Jan. 7 /PRNewswire/ -- Hologic Inc. (NASDAQ: HOLX), one of the leading manufacturers of bone densitometers, said today that the recent recommendation by the Health Care Finance Administration (HCFA) to reimburse for dual-energy x-ray examinations for the measurement of bone density should provide an important benefit for women at risk for osteoporosis.
 In the Dec. 2, 1993 announcement published in the Federal Register, HCFA recommended that, effective Jan. 1, 1994, dual-energy bone density examinations be reimbursed for Medicare patients nationwide.
 "This long-awaited decision reinforces the growing awareness of osteoporosis as a debilitating but treatable condition and represents a proactive step toward long-term healthcare savings," said S. David Ellenbogen, president and CEO. "Reimbursement for bone density examinations should provide an additional stimulant for growth in the bone densitometry market in the upcoming year. We attribute the recent increase in interest for our bone densitometers to this reimbursement policy and also to a rise in clinical trials for osteoporosis drug therapies by major pharmaceutical companies."
 "It is currently estimated that the cost to treat osteoporosis related fractures exceeds $10 billion annually in the United States alone. We are hopeful that this policy will prompt other insurance carriers to expand their coverage to include this preventative procedure." Osteoporosis occurs in one of three women over the age of 65 in the United States.
 Mark Duerst, Hologic's National Sales Manager, indicated that the market for bone densitometers had been sluggish throughout 1993 due to several factors including uncertainty over the Clinton Administration's healthcare reform initiative, the lack of approval for new osteoporosis drug therapies and the lack of Medicare reimbursement for bone density examinations. Hologic, like many other companies, focused on developing new international markets and new business segments in an effort to offset the domestic market conditions.
 "During the past year we developed several new sales territories in Latin America and the Pacific Rim -- areas where Hologic previously had little or no presence," commented Ellenbogen. "Additionally, in late 1993, Hologic engaged outside consultants to assist in the identification of acquisition candidates complementary to medical imaging and to our distribution network. While the company remains committed to bone densitometry, we feel the company's long-term growth potential will best be served if Hologic obtains a certain level of product diversification."
 Hologic, Inc. develops, manufactures and markets proprietary x-ray systems. With more than 1,500 installations worldwide, the company's QDR and DTX bone densitometers are used for the precise measurement of bone density to assist in the diagnosis and monitoring of osteoporosis and other metabolic diseases. Osteoporosis is a condition characterized by decreased bone density and increased risk of fractures.
 -0- 1/7/94
 /CONTACT: Marianne Ritchie of Hologic, 617-890-2300/
 (HOLX)


CO: Hologic Inc. ST: Massachusetts IN: MTC HEA SU:

JL-CM -- NE006 -- 0181 01/07/94 13:29 EST
COPYRIGHT 1994 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1994 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 7, 1994
Words:463
Previous Article:THE BARBERS ANNOUNCES ANNUAL SHAREHOLDERS MEETING
Next Article:U.S. TRANSPORTATION SYSTEMS, INC. ANNOUNCES ONE-FOR-FIVE REVERSE STOCK SPLIT
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters